Research for treatments, prevention and a cure
Page template: single.php
Search terms : 

CTN at IAS 2017

The International AIDS Society Conference on HIV Science features the latest HIV science, including basic, clinical, and prevention research. It is the largest open scientific conference on HIV and AIDS related issues, and it brings numerous professionals from all around the world gather together to focus on the moving of scientific advances into practice. This conference takes place every two years, and this year, the 9th IAS Conference will be taking place in Paris, France, from July 23 to July 26. This four-day event will feature a wide range of sessions, from special focus sessions, to workshops and oral abstract presentations. The CTN plays an integral part at the conference through our investigators and postdoctoral fellows presenting their material to other professionals.


CTN-Affiliated Pre-Conference Events

Dr. Marina Klein, National Co-Director of the CTN as well as co-leader of the Co-infections and Concurrent Diseases Core, will be co-chair for the 4th International HIV/Viral Hepatitis Co-Infection Meeting, which will take place on July 22 – 23, 2017. During this meeting, one of our postdoctoral fellows, Dr. Nadine Kronfli, will be presenting an oral abstract on Trends in Cause-Specific Mortality in HIV-hepatitis C (HCV) Co-infected Patients in Canada (2003 – 2016): Early Impact of HCV Therapy.  She will also be presenting another poster abstract on the topic, Does the Non-Alcoholic Fatty Liver Disease (NAFLD) Score Predict Liver Fibrosis Progression after Hepatitis C Virus (HCV) Treatment in Human Immunodeficiency Virus (HIV)-HCV Co-infected Patients? 


Conference Events

Dr. Sharon Walmsley, National Co-Director of the CTN as well as the Clinical Management Science Core Co-leader, has been heavily involved with IAS 2017 as a committee member of the Track B: Clinical Sciences Committee. Each committee and its members play an active role in the preparation of the conference programme, from the initial planning stage to the finalization of the conference content.

Dr. Marina Klein, National Co-Director of the CTN as well as the Confections and Concurrent Diseases Core Co-leaderwill be co-chairing the Bridging Session Hepatitis C Cure: Reality for Few and a Dream for Many. Wednesday, 26 July, 16:30 – 18:00

Dr. Richard Lester, CTN Investigator, will be presenting on Review of mHealth evidence: what we know, what we don’t know at the mHealth and the Global HIV Response: Harnessing the Promise of Mobile Technologies for Effective Programme Implementation.

Dr. Jean-Pierre Routy, Elected National Chair of the CTN Steering Committee and Vaccines and Immunotherapies Core Co-leader, will be co-chairing the Bridging Session Primary HIV Infection and Early Treatment. Tuesday, 25 July, 11:00 – 12:30 pm. Monday 24 July, 16:30 – 18:00.

Dr. Lena Serghides, CTN Investigator, will be presenting on ARVs, the in utero environment, and fetal programming – clinical and model findings at the 3rd HIV Exposed Uninfected (HEU) Child WorkshopSunday 23 July, 10:15 – 14:30.

EventDate & TimeDetails
3rd HIV Exposed Uninfected (HEU) Child WorkshopSunday, July 23
10:15 - 14:30
This workshop will continue the collaborative conversation around HIV-exposed uninfected (HEU) child health outcomes with a focus on connecting laboratory, clinical, and epidemiologic research to inform the appropriate public health response.
Dr. Lena Serghides will be presenting on ARVs, the in utero environment, and fetal programming - clinical and model findings.
HIV and the Liver: Co-Infection and ComplicationsMonday, July 24
14:30 - 16:00
CTN postdoctoral fellow Dr. Nadine Kronfli will be presenting on Trends in cause-specific mortality in HIV-hepatitis C (HCV) co-infected patients in Canada (2003-2016): early impact of HCV therapy.
MicrobiomeTuesday, July 25
14:30 - 16:00
This session is aimed t basic scientists and clinical researchers among others, to learn about the latest findings with regards to the role of the microbiome in HIV acquisition and pathogenesis, from animal models to potential therapeutic interventions in patients. Dr. Rupert Kaul will be conducting a review on clinical trials to improve the microbiome function.
The Key to Key PopulationsTuesday, July 25
14:30 - 16:00
Dr. Nathan Lachowsky will be giving a presentation on prevalence, trends, and risk factors of transactional sex among men who have sex with men in Metro Vancouver as a longitudinal event-level analysis.
PrEP Expectations and Experiences Wednesday, July 26
11:00 - 12:30
Dr. Darrell Tan will be presenting on preferences regarding emerging HIV prevention technologies among Toronto men who have sex with men.
IAS Members Meeting and Joep Lange Memorial LectureWednesday, July 26
13:00 - 14:30
This special session pays tribute to Joep Lange's contribution to HIV research and treatment, and his efforts to scale up access to health services and HIV treatment in resource limited settings, particularly in Asia and Africa. Dr. Marina Klein will be presenting a session to remember Dr. Mark Wainberg, one of the leading scientists in HIV research.


Presentations and Abstracts

Below is a list of oral and poster presentation abstracts from CTN-supported studies, CTN- affiliated researchers, and postdoctoral fellows.

Oral Presentations: (presenting author underlined)

G. Antoni, C. Tremblay, I. Charreau, E. Cua, D. Rojas-Castro, N. Hall, J. Chas, T. Huleux, B. Spire, C. Capitant, L. Cotte, L. Meyer, J.-M. Molina, ANRS IPERGAY Study Group. On-demand PrEP with TDF/FTC remains highly effective among MSM with infrequent sexual intercourse: a sub-study of the ANRS IPERGAY trial. TUAC0102.

A. Bitnun, F. Kakkar, J. Brophy, L. Samson, M.T. Hawkes, S.E. Read, D.G. Ransy, P. Sandstrom, J. Kim, C. Lavigne, S. Lavoie, P.A. Wender, H. Soudeyns, for the EPIC4 Study Group. Predictors of HIV reservoir size in peripheral blood of perinatally HIV-infected children: preliminary results from EPIC4 (Early Pediatric Initiation, Canada Child Cure Cohort Study). MOPEB0359.

J. Brophy, T. Lee, A. Bitnun, F. Kakkar, J. Singer, A. Alimenti, D. Money, W. Vaudry, L. Sauve, Canadian Pediatric and Perinatal HIV/AIDS Research Group. Is tenofovir use in pregnancy associated with preterm delivery? A Canadian perinatal HIV surveillance program analysis. WEPEB0559.

J. Joy, R. Liang, T. Nguyen, R. McCloskey, B. Brenner, T. Lynch, J. Gill, J. Buller, Z. Brumme, A. Burchell, S. Rourke, M. Loutfy, J. Raboud, C. Cooper, D. Kelly, C. Tsoukas, N. Machouf, M. Klein, A. Wong, P. Levett, S. Hosein, M. Wainberg, P. Sandstrom, J. Montaner, R. Hogg, A. Poon, P.R. Harrigan, C.A.N.O.C. Collaboration. Phylodynamic insights into HIV epidemic dynamics within Canada. WEPDX0104.

A. Kaida, D. Money, N. Pick, A. Carter, V.L. Kennedy, K. Webster, L. Wang, J. Zhu, R. Gormley, A. de Pokomandy, M. Loutfy, on behalf of the CHIWOS Research Team. Uptake of safer conception strategies among women living with HIV in Canada who report pregnancy with an HIV-serodiscordant partner. WEPEB0562.

N. Kronfli, S.R. Bhatnagar, M. Hull, E. Moodie, C. Cooper, N. Pick, S. Walmsley, M.-L. Vachon, V. Martel-Leferriere, J. Gill, M. Klein, on behalf of the Canadian Co-Infection Cohort Investigators. Trends in cause-specific mortality in HIV-hepatitis C (HCV) co-infected patients in Canada (2003-2016): early impact of HCV therapy. MOAB0302.

N. Kronfli, R. Nitulescu, S. Walmsley, C. Cooper, S. Haider, J. Gill, M.-L. Vachon, M. Klein, on behalf of the Canadian Co-Infection Cohort Investigators. Does the non-alcoholic fatty liver disease (NAFLD) score predict liver fibrosis progression after hepatitis C virus (HCV) treatment in human immunodeficiency virus (HIV)-HCV co-infected patients? WEPEB0519.

N.J. Lachowsky, L. Wang, J. Zhu, H. Armstrong, M. Taylor, G. Olarewaju, R. Hogg, E.A. Roth, D.M. Moore, Momentum Health Study. Prevalence, trends and risk factors of transactional sex among men who have sex with men in metro Vancouver, Canada: a longitudinal event-level analysis. TUAC0502.

N.J. Lachowsky, Z. Cui, J. Zhu, H. Armstrong, M. Taylor, J. Edwards, G. Olarewaju, R. Hogg, E.A. Roth, D.M. Moore, Momentum Health Study. Crystal methamphetamine initiation among HIV-positive and HIV-negative men who have sex with men in Vancouver, Canada: a longitudinal analysis. MOPEC0649.

J. Liang, A. Hassan, B. Brenner, J.-P. Routy, T. Mesplède, M.A. Wainberg.Early recovery of antibody-mediated neutralization and ADCC responses in HIV-positive individuals under dolutegravir-based antiretroviral therapy. TUPEA0162.

C. Martin, D. Peltier, N. O’Brien, A. Kaida, M. Becker, C. Bourassa, S. Bruce, M. Loutfy, A. de Pokomandy, on behalf of the CHIWOS-PAW Team. Sharing circles with indigenous women: understanding perceptions of HIV to inform the scale-up of behavioural change strategies in Quebec, Canada. WEPEC1057.

V. Mehraj, J. Cox, B. Lebouché, C. Costiniuk, W. Cao, T. Li, R. Ponte, R. Thomas, J. Szabo, J.-G. Baril, B. Trottier, P. Coté, R. LeBlanc, J. Bruneau, C. Tremblay, J.-P. Routy, Montreal Primary HIV-infection Study Group. Socioeconomic status and time trends associated with early ART initiation following primary HIV infection in Montreal, Canada: 1996-2015. MOPEB0243.

N. O’Brien, C. Martin, D. Peltier, A. Kaida, M. Becker, C. Bourassa, S. Bruce, M. Loutfy, A. de Pokomandy, on behalf of the CHIWOS-PAW Team. Lessons learned: employing Indigenous methodologies and women-centred approaches to understand Indigenous women’s experience of HIV prevention and care in Quebec, Canada. MOPEC0677.

T.J. O’Neill, J. Raboud, C. Cooper, M. Loutfy, M.B. Klein, R.H.H. Thein, A.N. Burchell, Canadian Observational Cohort Collaboration. Effect of sex and hepatitis C co-infection on HIV treatment and mortality: a 15-year follow-up. TUPEB0383.

C. Rossi, E. Moodie, M. Hull, V. Martel-Lafferriere, M.-L. Vachon, C. Cooper, N. Pick, S. Walmsley, M. Klein, Canadian Confection Cohort. Sustained virologic response (SVR) after hepatitis C virus (HCV) treatment does not lead to improved renal function in HIV/HCV connected patients. TUPEB0406.

D.H.S. Tan, J. Rana, S. Fowler, T.A. Hart, J. Wilton, A. Bayoumi. Preferences regarding emerging HIV prevention technologies among Toronto men who have sex with men. WEAC0102.

A. Underhill, V.L. Kennedy, J. Brophy, M. Loutfy, W. Wu, A. Carter, K. Proulx-Boucher, K. Webster, A. de Pokomandy, A. Kaida, on behalf of the CHIWOS Research Team. Sexual satisfaction: determining unique clinical needs of the first generation of young women living with HIV since childhood through the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS). TUPEB0475.


Research for treatments, prevention and a cure